Entera Bio Ltd. (ENTX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Entera Bio reported revenue of $42,000, down 76.8% from $181,000 the year before. Net income was -$11.4M (a -27235.7% net margin), or $0.25 per diluted share. Gross margin was 0.0% and operating margin was -27450.0%. Operating activities generated -$7.4M of cash, leaving -$7.5M of free cash flow. At fiscal year end, Entera Bio held $16.0M in total assets against $2.9M in total liabilities, including $7.1M of cash and equivalents.
Open the full interactive Entera Bio financials → Quarterly statements, key ratios, valuation history and price charts.
Entera Bio Key Stats
| Share Price | $2.49 |
|---|---|
| Market Cap | $125.6M |
| P/E Ratio | 10.0 |
| Revenue YoY Growth | -76.8% |
| 52-Week Range | $1.00 – $3.92 |
| Shares Outstanding | 50.5 million (basic, 2026 Q2) |
Entera Bio Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $571,000 | $134,000 | $0 | $181,000 | $42,000 |
| Gross Profit | $198,000 | $33,000 | $0 | $9,000 | $0 |
| Operating Income | -$12.2M | -$13.0M | -$8.9M | -$9.6M | -$11.5M |
| Pre-Tax Income | -$12.2M | -$12.9M | -$8.9M | -$9.5M | -$11.4M |
| Income Tax | -$59,000 | $137,000 | $29,000 | $14,000 | $0 |
| Net Income | -$12.2M | -$13.1M | -$8.9M | -$9.5M | -$11.4M |
| Diluted EPS | -$0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
Entera Bio Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.2M | -$3.0M | -$3.5M | -$7.3M |
| Diluted EPS | $0.07 | -$0.07 | $0.07 | $0.14 |
Entera Bio Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M |
| Current Assets | $25.3M | $12.8M | $11.3M | $9.0M | $15.3M |
| Total Assets | $26.0M | $13.1M | $11.8M | $9.4M | $16.0M |
| Current Liabilities | $3.2M | $1.3M | $1.1M | $1.2M | $2.2M |
| Total Liabilities | $3.4M | $1.4M | $1.4M | $1.3M | $2.9M |
| Shareholders' Equity | $22.6M | $11.8M | $10.4M | $8.1M | $13.1M |
Entera Bio Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.4M |
| Cash From Investing | -$17,000 | -$102,000 | -$17,000 | -$3,000 | -$107,000 |
| Cash From Financing | $25.4M | $13,000 | $6.0M | $4.5M | $13.7M |
| Free Cash Flow | -$9.1M | -$12.5M | -$7.3M | -$6.8M | -$7.5M |
Figures from Entera Bio's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Entera Bio financials page for every line item.
Entera Bio Company Profile
| Ticker | ENTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Jerusalem |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001638097 |
Frequently Asked Questions
What was Entera Bio's revenue in fiscal 2025?
Entera Bio (ENTX) reported revenue of $42,000 for fiscal 2025.
What is Entera Bio's annual revenue history?
Entera Bio's annual revenue by fiscal year: 2021: $571,000; 2022: $134,000; 2023: $0; 2024: $181,000; 2025: $42,000.
What was Entera Bio's net income in fiscal 2025?
Entera Bio reported net income of -$11.4M for fiscal 2025.
What was Entera Bio's earnings per share (EPS) in fiscal 2025?
Entera Bio's diluted EPS was $0.25 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Entera Bio generate in fiscal 2025?
Entera Bio generated -$7.5M of free cash flow in fiscal 2025.
What was Entera Bio's revenue last quarter?
In its most recent reported quarter (2026 Q2), Entera Bio reported revenue of $0.
How many shares of Entera Bio are outstanding?
Entera Bio reported a weighted average of 50.5 million basic shares outstanding in 2026 Q2.
What is Entera Bio's market cap?
Based on its latest closing price, Entera Bio (ENTX) has a market capitalization of about $125.6M.
When does Entera Bio's fiscal year end?
Entera Bio's fiscal year end, as registered with the SEC, is December 31.
Where is Entera Bio headquartered?
Entera Bio lists its business address in Jerusalem in its SEC filings.
Entera Bio Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →